SCHEMBL3450099

SCHEMBL3450099

CCOC(=O)C=Cc1cccc(-c2cnc(Nc3ccc(F)c(OC)c3)nc2N2CCOCC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
BTK Q06187 3/20 0.42
JAK3 P52333 2/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
MTOR P42345 1/20 0.41
PAK1 Q13153 1/20 0.41
MAPK8 P45983 2/20 0.40
MAPK10 P53779 2/20 0.40
CCNT1 O60563 2/20 0.40
CCNA2 P20248 2/20 0.40
CDK2 P24941 2/20 0.40
CDK9 P50750 2/20 0.40
RAF1 P04049 1/20 0.40
BRAF P15056 1/20 0.40
JUN P05412 1/20 0.40
PRKDC P78527 1/20 0.40
SYK P43405 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13311399 1.00 NPC1 (0.44) NPC1RAB9ASMN1; SMN2BTKJAK3
SCHEMBL3448484 0.92 NPC1 (0.42) NPC1RAB9ASMN1; SMN2BTKJAK3
SCHEMBL3448486 0.92 NPC1 (0.42) NPC1RAB9ASMN1; SMN2BTKJAK3
SCHEMBL13420526 0.92 SYK (0.42) NPC1RAB9ASMN1; SMN2BTKJAK3
SCHEMBL3448026 0.91 NPC1 (0.41) NPC1RAB9ASMN1; SMN2BTKJAK3
SCHEMBL13311549 0.91 NPC1 (0.41) NPC1RAB9ASMN1; SMN2BTKJAK3
SCHEMBL3448029 0.91 NPC1 (0.41) NPC1RAB9ASMN1; SMN2BTKJAK3
SCHEMBL13310949 0.91 BTK (0.44) NPC1RAB9ASMN1; SMN2BTKJAK3
SCHEMBL13311461 0.91 NPC1 (0.47) NPC1RAB9ASMN1; SMN2BTKJAK3
SCHEMBL3447300 0.90 NPC1 (0.43) NPC1RAB9ASMN1; SMN2BTKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD NPC1 603/4885RAB9A 2449/4885SMN1; SMN2 3328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.